The Coach's Guide to Peptides: How to Advise Without Prescribing

The question coaches get

Sooner or later, an athlete asks a coach or trainer about a peptide. Often it's BPC-157 for a sore tendon, or a growth hormone secretagogue such as ipamorelin that a training partner has been talking up. How the coach answers matters for the athlete's health. In tested sport, it can also decide whether the coach keeps working.

The World Anti-Doping Code counts any coach, trainer, manager, team staff member, medical worker or parent who assists a competing athlete as "Athlete Support Personnel." If your athletes compete under a federation or national anti-doping organization that has adopted the Code, its rules generally reach you too. For the wider legal picture, start with our overview of legal implications of peptide use in sports.

Where common peptides sit on the 2026 list

As of October 2026, WADA's 2026 Prohibited List is in force. Every peptide in the table below is prohibited at all times, in and out of competition.

An earlier version of this page said BPC-157 was "not explicitly named" on the WADA list. That was wrong: the S0 section names it directly. TB-500 is often lumped in with S0 as well, but WADA places it under S2.3. The difference matters because S0 substances are Specified Substances and S2 substances are not, which changes how sanctions are calculated.

The 2027 Prohibited List has been published and takes effect on January 1, 2027. According to USADA's athlete advisory, it names "peptides" in general within S0, and a peptide missing from the list by name may still be prohibited. Athletes are strictly liable for whatever turns up in their samples, so arguing that a compound wasn't listed is unlikely to help.

What the anti-doping rules expect from coaches

A positive test is only one way to break the rules. Several violations in Article 2 of the Code apply to support staff directly, and none needs the athlete to test positive:

• Possession (Article 2.6.2). Holding a prohibited substance in connection with an athlete or their training, without a Therapeutic Use Exemption or other acceptable justification.
• Trafficking (Article 2.7). The definition includes giving or delivering a prohibited substance to someone else. Passing on a vial counts, even for free.
• Administration (Article 2.8). "Providing, supplying, supervising, facilitating, or otherwise participating in" another person's use. Helping with reconstitution or an injection can fall here.
• Complicity (Article 2.9). Assisting, encouraging or covering up another person's violation. WADA's comment says this "may include either physical or psychological assistance."
• Prohibited association (Article 2.10). Athletes may not work with coaches who are banned or who have been convicted or disciplined for doping-related conduct.

Under the 2027 Code, which takes effect on January 1, 2027, trafficking or administration carries a ban of at least four years and up to life. When the athlete is a minor or protected person and the substance isn't a Specified Substance, a support person who traffics or administers it faces a lifetime ban. Complicity carries at least two years. The 2021 Code, in force until then, contains the same violations.

Article 21.2 adds positive duties. Support staff must know the rules that apply to them and their athletes, cooperate with testing, and avoid using or possessing prohibited substances without valid justification. The 2027 Code adds a duty to attend anti-doping education and give athletes accurate information, "particularly in the case of Protected Persons and Minors." According to WADA's summary of the changes, anti-doping organizations must also automatically investigate support staff when a minor or protected person they support commits a violation, or when more than one of their athletes does.

In the United States, the Rodchenkov Anti-Doping Act of 2020 adds a criminal layer. It makes it a federal crime for anyone other than the athlete to knowingly carry out, or conspire in, a scheme to influence a major international competition with a prohibited substance or method, including conduct outside the US.

Three ways coaches respond

Refusing to discuss it. A flat "don't ask me about that" feels like the safe legal position. In practice, the athlete still has the sore Achilles and now reads up on dosing alone, usually on forums. The coach loses the chance to correct bad information or notice side effects. It also fits poorly with the 2027 Code's expectation that support staff give athletes accurate information.

Facilitating. This is the coach who recommends a protocol, shares a vendor or helps with the injection. Each of those acts maps onto a violation listed above, and it can expose the coach to legal claims outside sport if the product causes harm.

Educating without prescribing. The coach talks openly about what the research and the rules say, but won't supply or dose anything. The athlete still decides, with better information, and the coach stays close enough to spot problems.

How the conversation can go

The aim is to give accurate context, then steer attention back to what the coach can influence, such as training load and rehab.

When the question is BPC-157

A response that crosses the line names an amount or a seller. A better response starts with where the evidence comes from, which is almost entirely animals. The 2003 study often cited for tendon healing used rats with cut Achilles tendons. A 2025 systematic review in orthopaedic sports medicine found 35 preclinical studies and one small clinical study, and no clinical safety data. For a tested athlete, the coach should also say plainly that WADA names BPC-157 in S0. Then the conversation can move to the rehab plan and whether the athlete has seen a physiotherapist.

When the question is a growth hormone secretagogue

Athletes ask about combinations such as ipamorelin with CJC-1295 for getting leaner. Recommending a stack or a timing crosses the line. The educational version notes that both sit in S2.2.4. In human studies, this class reliably raises growth hormone and IGF-1, but trials have mostly not shown better strength or more fat loss. In a two-year trial in healthy older adults, the related compound MK-677 lowered insulin sensitivity. Ipamorelin's Phase 2 trial in surgery patients missed its primary endpoint, and development stopped.

When the question is about doses

A coach can report what's known without turning it into an instruction. For BPC-157, users commonly report 250-500 mcg a day by subcutaneous injection, and no human dose-finding study exists. That's reporting. "You should take X" is a prescription, and coaches aren't licensed to prescribe. Converting rodent doses into human doses doesn't help either, because nobody has tested those conversions in people.

Boundaries worth setting early

• Don't supply. Giving an athlete a peptide can be trafficking, and holding it for them can be possession. FDA says it lacks enough safety information on BPC-157 and flags possible immunogenicity and impurity problems, so a coach who hands over a vial is vouching for a product no regulator has reviewed.
• Be clear about your obligations. Tell tested athletes early that you won't help hide use and that the Code expects you to cooperate with testing. Point them to their national anti-doping organization's medication lookup (USADA directs US athletes to Global DRO) and to the Therapeutic Use Exemption process for prescription medicines.
• Keep a record. A short follow-up email can list what was discussed, link the sources, and restate that you don't give medical advice. It won't protect anyone who actually supplied a substance, but it documents what you said.

None of this is legal advice. A federation's anti-doping office can tell you which rules apply to your role.

Untested athletes and gym clients

Personal trainers who work with recreational lifters may not be bound by the Code. That doesn't make supplying peptides safe or lawful. As of October 2026, BPC-157 isn't approved as a drug anywhere, and FDA's compounding page says the agency lacks enough information to know whether it would cause harm in people.

Recreational clients also face the product-quality problem, because vials sold "for research use only" aren't made or checked as medicines. Our risk assessment of peptide use covers side effects and product quality, and the ethics of peptides in sport looks at consent for athletes outside testing pools. Rules also vary by country, which we compare in peptide laws and anti-doping rules worldwide.

What to watch next

• The 2027 Prohibited List and the 2027 Code both take effect on January 1, 2027, including the new education duties in Article 21.2.
• College and professional leagues, including the NCAA, run their own policies and testing. We didn't review them for this update, so check with the athlete's governing body.
• FDA's position on compounding BPC-157 could change. As of October 2026, it isn't approved as a drug or on the 503A bulks list.